Navigation Links
Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
Date:5/8/2013

igen business, including, without limitation: the possibility that the FDA determines not to initiate review of the Contrave NDA until it has received the complete study report for the interim analysis; the SPA is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; Orexigen's ability to conduct the Light Study and the progress and timing thereof, including risks associated with enrolling and retaining the appropriate patients in the Light Study; Orexigen's ability to demonstrate in the Light Study that the risk of MACE in overweight and obese patients treated with Contrave does not adversely affect Contrave's benefit-risk profile; the potential that earlier clinical trials may not be predictive of future results in the Light Study; the potential for the FDA to not approve Contrave even after the resubmission with the MACE data; the potential for the Light Study to cost more than what is projected; the potential for early termination of Orexigen's North American collaboration agreement with Takeda Pharmaceutical Company Limited; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of the Contrave NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to maintain sufficient capital to fund our operations through potential approval of Contrave in 2014; the development plan for Empatic; Orexigen's ability to enter into a collaborative partnership for Empatic on acceptable terms, if at all; and other risks described in Orexigen's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news rele
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
7. Fate Therapeutics Strengthens Its iPSC Platform
8. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
9. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
10. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
11. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... BlueInGreen, LLC ( BlueInGreen® ) and ... PCI, Inc., leading suppliers of ozone process technology ... to provide a new state-of-the-art ozone system for ... Wastewater Treatment. The new ozone disinfection system ... dissolution technology, Pinnacle Ozone’s industry leading Zenith™ ozone ...
(Date:11/21/2014)... 2014 2014 Deep Research Report ... in-depth research report on the transformer market. The ... application, and industry chain structure as well as ... analysis, including China’s domestic market as well as ... situation analysis. The report also covers information on ...
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014  Cytori Therapeutics ... Marc Hedrick , M.D. will present live at VirtualInvestorConferences.com ... 4, 2014 TIME:    11:15 am PT / 2:15 ... this URL into your browser,s address bar: http://bit.ly/1B2KGaL ... time and receive event updates. This will ...
(Date:11/18/2014)... Sarasota, FL (PRWEB) November 17, 2014 ... novel point-of-care diagnostic tests – today announces its ... Control and Prevention’s (CDC) Get Smart About Antibiotics ... Antibiotics Week is a national campaign designed to ... local health departments, and non-profit and for-profit partners ...
Breaking Biology Technology:City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3
... Calif., June 3, 2011 Masimo (NASDAQ: MASI ) ... William Blair & Company 31st Annual Growth Stock Conference at the ... a.m. Central Time.  A live audiocast of the presentation will be ... of the audiocast will be available following the live presentation. ...
... HOUSTON, June 2, 2011 Working to better predict ... biologist and his team have discovered some surprising things ... possible to predict the progression of chronic disease. ... describe their findings in a paper titled "Negative Epistasis ...
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ... shares of its common stock in an underwritten public offering. ... to purchase up to an additional 15% of the shares ... over-allotments, if any.  Citi and Leerink Swann LLC are acting ...
Cached Biology Technology:Masimo to Present at William Blair & Company 31st Annual Growth Stock Conference 2Work by UH evolutionary biologist may one day help with chronic diseases 2Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
(Date:11/7/2014)... Nov. 7, 2014  In conjunction with the ... Departments, The Community Foundation of the Verdugos has announced the ... JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo Regional ... its first six months of existence, the Lab has processed ... for local law enforcement. "Because our number one ...
(Date:11/6/2014)... 6, 2014 - Insilico Medicine, Inc, a Baltimore-based ... age related diseases announced a research collaboration with ... Champions Oncology, Inc (OTC: CSBR). , "There are ... medicine, but Champions Oncology,s TumorGraft technology is unique ... chemotherapy regimen experimentally generating vast amounts of valuable ...
(Date:11/4/2014)... right amount of death at the right time might ... new research that could help in understanding animal populations, ... In a paper in the journal Trends in ... European colleagues conclude that the kind of positive population ... individuals, or mortality, depends on the size and developmental ...
Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2When less is more: Death in moderation boosts population density in nature 2
... have found that humans aren,t the only ones who can ... too. This capability was previously believed to be specific to ... mimic sound seem to be able to keep a beat, ... study was led by Adena Schachner, a doctoral candidate in ...
... Following a successful second funding period, the first three ... continue for another four years. This decision was made ... German Research Foundation) at its spring session in Bonn. ... Ocean in the Earth System" in Bremen, "The Center ...
... the spring allergy season, things are looking up. A research ... Journal of Leukocyte Biology ( http://www.jleukbio.org ) shows how ... cellular switch that turns allergies and asthma both on and ... for some people with asthma and allergies, their problems might ...
Cached Biology News:Some vocal-mimicking animals, particularly parrots, can move to a musical beat 2Some vocal-mimicking animals, particularly parrots, can move to a musical beat 3The first DFG research centers to be funded for another four years 2The first DFG research centers to be funded for another four years 3The first DFG research centers to be funded for another four years 4Just in time for spring: Scientists find the cellular on and off switch for allergies and asthma 2
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
... Desselberger (1995) • This book is ... classical and molecular techniques currently used ... and analysis of virus-specific antibodies and ... presented covering immunoassays, blotting and hybridization ...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
Bovine Serum...
Biology Products: